mProX™ Human PDK2 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

PDK2, or pyruvate dehydrogenase kinase 2, has various applications in different fields. In the field of neurodegeneration, PDK2 has been identified as a target for treating neurological diseases by regulating energy metabolism and repairing mitochondrial damage. In a study, a small molecule called scutellarin (SG) was found to rescue mitochondrial damage and restore mitochondrial homeostasis through its activity on PDK2. This indicates that targeting the PDK2 pathway could be a potential therapeutic approach for neurological injury and cognitive impairment. In cancer therapy, inhibition of PDK2 was shown to break mitochondrial metabolic plasticity and sensitize cancer cells to glucose restriction therapy. By disrupting the SIRT1/PDK2/PARL axis, the mitochondrial fusion process was inhibited, leading to increased susceptibility of cancer cells to glucose restriction therapy. This suggests that targeting PDK2 and mitochondrial dynamics could be a synergistic approach in cancer treatment. In the context of autosomal dominant polycystic kidney disease (ADPKD), PDK2 variants were found to affect normal splicing of PKD1 and PKD2 genes, emphasizing the importance of assessing the effect of PDK2 variants on exon splicing in understanding the disease. Finally, PDK2 was found to be involved in stress-induced impaired brain energy metabolism in depression. Increased PDK2 expression and subsequent PDH phosphorylation was observed in response to dysregulated hypothalamus pituitary adrenal axis and glucocorticoids release. Silencing PDK2 restored neuronal oxidative phosphorylation and improved energy metabolism in a depression model. Overall, the applications of PDK2 include treating neurological diseases, sensitizing cancer cells to therapy, understanding genetic diseases, and addressing impaired brain energy metabolism in depression.